Insider Analysis From Morrison & Foerster LLP: China’s Bolar Exemption - Beware of the Uncertainties of Its Reach And Scope (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
By Janet Xiao, Morrison & Foerster LLP, Palo Alto and Michael Vella, Morrison & Foerster LLP, Shangha
You may also be interested in...
A Weak Link: Chinese Courts Reluctant To Grant Preliminary Injunctions In Pharma IP Cases
With a large number of pharma patents about to expire in China, hurdles to obtaining injunctive relief could be a huge problem, according to the EU Chamber of Commerce in China.
A Weak Link: Chinese Courts Reluctant To Grant Preliminary Injunctions In Pharma IP Cases
With a large number of pharma patents about to expire in China, hurdles to obtaining injunctive relief could be a huge problem, according to the EU Chamber of Commerce in China.
68 Billon Dollar Question: Could China's Government Block Worldwide Merger Of Wyeth And Pfizer?
BEIJING - Tucked away toward the end of the $68-billion merger agreement between Pfizer Inc. and Wyeth is a clause that could give the Chinese government the ultimate power to approve or block this worldwide union of American pharmaceutical giants